Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

被引：0

作者：

Papageorgiou, Loula ^{[1
,2
]}

Fotiou, Despina ^{[3
]}

Van Dreden, Patrick ^{[4
]}

Garderet, Laurent ^{[5
,6
]}

Dimopoulos, Meletios A. ^{[3
,7
]}

Elalamy, Ismail ^{[8
]}

Mohty, Mohamad ^{[9
,10
,11
]}

Gerotziafas, Grigoris ^{[12
,13
]}

机构：

[1] Univ Pierre & Marie Curie UPMC, Paris Fac Med Pierre & Marie Curie, Inst Univ Cancerol IUC, Sorbonne Univ,Canc Biol & Therapeut,INSERM U938, Paris, France

[2] Tenon Univ Hosp, AP HP, Dept Haematol, Paris, France

[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[4] Stago, Clin Res, Gennevilliers, France

[5] Hop Pitie Salpetiere, AP HP, Serv Hematol, Paris, France

[6] Hop St Antoine, Ctr Rech St Antoine, Team Proliferat & Differentiat Stem Cells, Paris, France

[7] Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece

[8] Paris 6 Univ, AP HP, Paris 20, France

[9] St Antoine Hosp, Dept Haematol, INSERM UMR 938, Paris, France

[10] St Antoine Hosp, EBMT Paris Study Off CEREST TC, INSERM UMR 938, Paris, France

[11] Univ Paris 06, Paris, France

[12] Sorbonne Univ, Inst Univ Cancerol, INSERM, Canc Haemostasis & Angiogenesis Res Grp, Paris, France

[13] Hop Tenon, AP HP, Thrombosis Ctr, Serv Hematol Biol, Paris, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126954

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1913

引用

页数：3

共 50 条

[21] Multicenter randomized double-blind placebo controlled study on efficacy of GM-CSF for collection of peripheral blood progenitor cells (PBPC) in multiple myeloma (MM) patients.
Marit, G
To, LB
Flesch, M
Maloisel, F
Boiron, JM
Juttner, C
Reiffers, J
BONE MARROW TRANSPLANTATION, 1998, 21 : S200 - S200
[22] Multicenter randomized double-blind placebo controlled study on efficacy of GM-CSF for collection of peripheral blood progenitor cells (PBPC) in multiple myeloma (MM) patients.
Marit, G
To, LB
Brion, A
Lioure, B
Boiron, JM
Juttner, C
Blanc, AS
Reiffers, J
BLOOD, 1998, 92 (10) : 302B - 302B
[23] A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab-Bortezomib-Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide
Rizzello, Ilaria
Sacchetti, Ilaria
Barbato, Simona
Solli, Vincenza
Stefanoni, Paola
Cani, Lorenzo
Pavan, Laura
Quaresima, Micol
Belotti, Angelo
Sgherza, Nicola
Gentile, Massimo
Barila, Gregorio
Patriarca, Francesca
Celli, Melania
Vincelli, Iolanda Donatella
Mancuso, Katia
Sartor, Chiara
Pantani, Lucia
Tacchetti, Paola
Talarico, Marco
Puppi, Michele
Bigi, Flavia
Cavo, Michele
Zamagni, Elena
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S275 - S275
[24] Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials*
Gengenbach, Laura
Reinhardt, Heike
Ihorst, Gabriele
Ajayi, Stefanie
Dold, Sandra Maria
Koehler, Martin
Einsele, Hermann
Duyster, Justus
Waesch, Ralph
Engelhardt, Monika
LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2692 - 2699
[25] STUDY OF EFFICACY AND SAFETY OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) SCHEME AS TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (MM) IN RELAPSE. EXPERIENCE OF A SINGLE CENTRE
Maria Jose, Moreno Belmonte
Valentin, Cabanas-Perianes
Piqueras Mercedes, Berenguer
Raul, Perez-Lopez
Fierrez Eduardo, Salido
Faustino, Garcia-Candel
Juan Jose, Cerezo Manchado
Ana Maria, Garcia-Hernandez
Arnao Maria, Moya
Marin Amelia, Martinez
Poveda Elena, Fernandez
Almenzar Begona, Navarro
Amor Antonia, Melero
Camacho Fernanda, Ibanez
Ana Belen, Martinez Garcia
Alfredo, Minguela
Esparza Carmen, Munoz
Jose Maria, Moraleda Jimenez
HAEMATOLOGICA, 2016, 101 : 102 - 102
[26] Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT).
Zangari, M
Tricot, G
Zeldis, J
Eddlemon, P
Saghafifar, F
Barlogie, B
BLOOD, 2001, 98 (11) : 775A - 775A
[27] A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma (MM) patients.
Mateos, MV
Hernández, M
Díaz Mediavilla, J
Palomera, L
Moro, MJ
Hernández, J
Lahuerta, JJ
De la Rubia, J
Terol, MJ
Sureda, A
Bargay, J
Arriba, F
Alegre, A
Rivas, P
García-Laraña, J
Ribera, JM
Carrera, D
Bladé, J
Prósper, F
Esseltine, DL
van de Velde, H
Schenkein, D
San Miguel, JF
BLOOD, 2005, 106 (11) : 232A - 232A
[28] The revised myeloma comorbidity Index (R-MCI) in comparison with other comorbidity indices (CI) as a new approach for predicting overall survival (OS) and reducing treatment complications in multiple myeloma (MM) patients (pts)
Schoeller, K.
Ihorst, G.
Scheubeck, S.
Holler, M.
Woerner, S. M.
Reinhardt, H.
Mueller, S.
Duyster, J.
Waesch, R.
Engelhardt, M.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 189 - 189
[29] Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study
Van Dreden, Patrick
Papageorgiou, Loula
Lefkou, Eleftheria
Fotiou, Despina
Kastritis, Efstathios
Terpos, Evangelos
Rousseau, Aurelie
Sabbah, Michele
Grusse, Matthieu
Elalamy, Ismail
Mbemba, Elisabeth
Dimopoulos, Meletios Athanasios
Gerotziafas, Grigoris
BLOOD, 2023, 142
[30] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
Bahlis, Nizar
Samaras, Christy
Reece, Donna
Sebag, Michael
Matous, Jeffrey
Berdeja, Jesus
Shustik, Jesse
Schiller, Gary
Ganguly, Siddhartha
Song, Kevin
Seet, Christopher
Acosta-Rivera, Mirelis
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Liu, Hongjuan
Gentili, Christian
Siegel, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162

← 1 2 3 4 5 →